Loading patent…
AssigneeOhio State Innovation Foundation
InventorsThomas CHERPES, Rodolfo D. VICETTI MIGUEL, Natividad RUIZ
Estimating the term…
Disclosed herein is a recombinant Chlamydia-activated B cell (CAB) platform, vaccines, and methods of using the same. Disclosed is a method of enhancing a population of B cells, comprising exposing said B cells to a recombinant polypeptide derived from a Chlamydia spp. under conditions suitable to enhance the population of B cells, such that expansion and differentiation of said B cells takes place, and said B cells are exposed or crosslinked to an antigen. Also disclosed are methods to use a recombinant polypeptide derived from a Chlamydia spp. as an adjuvant for induction of enhanced humoral immunity against an unrelated antigen (e.g., humoral immunity against HIV antigen). Also disclosed are methods of producing said CABs, and treating a subject in need thereof with said CABs.
1-8. (canceled)
A platform for creating activated, antigen-presenting cells (APCs), wherein the platform comprises:
A method for producing activated, antigen-presenting Chlamydia-activated B cells in a subject, the method comprising:
27-32. (canceled)
A vaccine comprising an antigen and a polypeptide comprising a derivative of naturally occurring major outer membrane protein (MOMP) of a Chlamydia spp. or an antigenic fragment thereof, wherein the naturally occurring MOMP is modified so that at least one cysteine residue of MOMP is replaced with a different amino acid, and wherein the antigen is not derived from a Chlamydia spp.
-41. (canceled)
43-47. (canceled)
Dependencies are inferred from the claim text.